Krystal Biotech Reports GAAP EPS of $1.79, Beats Estimates but Revenue Misses
Krystal Biotech (KRYS) reported second-quarter earnings per share (GAAP) of $1.79, exceeding estimates by $0.16 and showing strong performance in profitability. However, the company's revenue came in at $119.22 million, missing expectations by $1.82 million despite a 24.1% year-over-year increase. The global sales of VYJUVEK reached $119.2 million for Q2 and have totaled $965.9 million since its launch. The company provided FY 2026 guidance, projecting non-GAAP R&D and SG&A expenses between $175.0 million to $195.0 million. Krystal Biotech's shares fell by approximately 2% following the earnings report.
Tickers: $KRYS